All filters
Videos
Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS | Michelle Rudek, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
Drug-Drug interactions with targeted oncolytics (in particular PPIs and TKIs) | Ron Mathijssen
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
Clinical relevance of liquid biopsy in cancer patients | Catherine Alix-Panabières, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
The value of surrogate endpoints in the benefit-risk assessment of new drugs | Gabe Sonke, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
How studies can be optimized by simultaneous use of PK/PD outcome measurement? | Alwin Huitema
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Exposure-Response Analysis of Lee 1810, a Lead Spectinamide Antibiotic in Mycobacterium tuberculosis Infected Mice- Santosh Wagh
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017
Slidesets
Improved efficacy of a cofactor-independent InhA inhibitor revealed by the C3HeB/ FeJ mouse model- Gregory Robertson
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017
Slidesets
High dose rifampicin for the treatment of TB meningitis: a dose finding study- Rob Aarnoutse, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017
Slidesets
Ototoxicity is associated with exposure to kanamycin and capreomycin in the treatment of multidrug-resistant tuberculosis- Mohammed Aslshaer
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017
Slidesets
A Cardiac Risk Algorithm to Predict the Probability of Drug-Induced Torsades de Pointes with Novel Anti-TB Agents- Alexander Berg, PharmD, PhD, FCP
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017
Slidesets
Pharmacokinetics of rifampicin in African children - Evaluation of the new WHO dosing guidelines- Paolo Denti
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017
Slidesets
Quantitative Analysis of MGIT Time to Positivity Using a Two-Part Longitudinal Model in Patients with Pulmonary Tuberculosis: A Meta-Analysis of 11 Clinical Studies Including 30 Unique Regimens- Nastya Kassir, PharmD, PhD, FCP
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017
Slidesets
Prediction of increase in time-to-positivity after higher doses of rifampicin based on pharmacokinetic-pharmacodynamic modelling- Robin Svensson
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017
Slidesets
Influence of Bacterial Growth Rate on Dose Optimization of Linezolid for Treatment of Tuberculosis- Kristina Bigelow
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017
Slidesets
ADA-formation and its effect on Mab PK | Maria-Jesus Garrido, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Clinical case discussions | Howard Gurney, MBBS, FRACP
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Evaluation of a physiological based pharmacokinetic model to evaluate the influence of covariates on sunitinib exposure
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Optimal design – potential application in oncology drug development and clinical practice | Andrew Hooker, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Assessment of the release of daunorubicin from liposomes after administration of daunoXome® using population pharmacokinetics
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Model-based TDM for oncology drugs | Ron Keizer, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Physiologically based PK model vs. Population PK approach during drug development | Italo Poggesi, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Opening Lecture: Inter- and intravariability in PK | Mark Ratain, MD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017